Abstract
Overweight and obesity have become a major health problem in this country and worldwide. Excess body fat and consequent adiposopathy increase the risk for and exacerbate many chronic health conditions, in particular type 2 diabetes mellitus (T2DM), dysmetabolic syndrome, and cardiovascular disease. Weight loss decreases inflammation and improves insulin resistance, glucose control, blood pressure, and dyslipidemia. Endocrinologists are the experts in the management of metabolic syndrome. Consequently, endocrinologists are particularly suited to take the lead in the management of obesity as a chronic disease. With several new pharmacologic agents available in recent years, it is essential that endocrinologists familiarize themselves with the treatment options and become comfortable with the pharmacologic as well as lifestyle approach to chronic weight management.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Reading List
Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2011;20:330–42.
Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity. 2013;21:2163–71.
Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean MEJ, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843–54.
Bartels CL, Miller SJ. Dietary supplements marketed for weight loss. Nutr Clin Pract. 2003;18(2):156–69.
Davies MJ, Bergenstal R, Bode B, Kushner R, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. JAMA. 2015;314:687–99.
Derosa G, Cicero AF, D’Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther. 2012;37(2):187–95.
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363–70.
Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (US). Clinical guidelines on the identification, evaluation, and treatment of overweight and Obesity in adults. Bethesda: National Institutes of Health, National Heart, Lung, and Blood Institute; 1998.
Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR. Anderson CM for the BLOSSOM clinical trial group: a one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77.
Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.
Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014a;37(12):3309–16.
Garvey WT, Ryan DH, Henry R, Bohannon NJV, Toplak H, Schwiers M, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014b;37:912–21.
Gonzalez-Campoy JM, Richardson B, Richardson C, Gonzalez-Cameron D, Ebrahim A, Strobel P, et al. Bariatric endocrinology: principles of medical practice. Int J Endocrinol. 2014;2014:917813.
Greenway FL, Fujoka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight an dobese adults (COR-I): a multicenter, arandomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26(2):262–73.
Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupriopion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023.
Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. Association of Clinical Endocrinologists’ position statement on obesity and obesity medicine. Endocr Pract. 2012;18(5):643.
O’Meara S, Riemsma R, Shirran L, Mather L, TerRiet G. A systemic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004;5:51–68.
O’Neil PM, Smith SR, Weissman NK, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of loracserin for weight loss in type 2 diabetes mellitus: the Bloom-DM study. Obesity. 2012;20:1426–36.
Pi-Sunyer X, Astrup A, Fujioka K, et al., for the SCALE Obesity and Prediabetes NN8022–1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang M, Stubb S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. NEJM. 2010;363:245–56.
Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–604.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.
TOS Obesity as a Disease Writing Group, Allison DB, Downey M, Atkinson RL, Billington CJ, Bray GA, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity. 2008;16:1161–77.
van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effect of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2013;162:1–10.
Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O’Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110–20.
Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37:1443–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Brett, E.M. (2019). Pharmacotherapy for Weight Management. In: Gonzalez-Campoy, J., Hurley, D., Garvey, W. (eds) Bariatric Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-95655-8_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-95655-8_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95653-4
Online ISBN: 978-3-319-95655-8
eBook Packages: MedicineMedicine (R0)